Polatuzumab vedotin-based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience.

MLA

Wang, Yu-Wen, et al. “Polatuzumab Vedotin-Based Salvage Immunochemotherapy as Third-Line or beyond Treatment for Patients with Diffuse Large B-Cell Lymphoma: A Real-World Experience.” Annals of Hematology, vol. 101, no. 2, Feb. 2022, pp. 349–58. EBSCOhost, https://doi.org/10.1007/s00277-021-04711-9.

APA

Wang, Y.-W., Tsai, X. C.-H., Hou, H.-A., Tien, F.-M., Liu, J.-H., Chou, W.-C., Ko, B.-S., Chen, Y.-W., Lin, C.-C., Cheng, C.-L., Lo, M.-Y., Lin, Y.-C., Lu, L.-C., Wu, S.-J., Kuo, S.-H., Hong, R.-L., Huang, T.-C., & Yao, M. (2022). Polatuzumab vedotin-based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience. Annals of Hematology, 101(2), 349–358. https://doi.org/10.1007/s00277-021-04711-9

Chicago

Wang, Yu-Wen, Xavier Cheng-Hong Tsai, Hsin-An Hou, Feng-Ming Tien, Jia-Hau Liu, Wen-Chien Chou, Bor-Sheng Ko, et al. 2022. “Polatuzumab Vedotin-Based Salvage Immunochemotherapy as Third-Line or beyond Treatment for Patients with Diffuse Large B-Cell Lymphoma: A Real-World Experience.” Annals of Hematology 101 (2): 349–58. doi:10.1007/s00277-021-04711-9.